CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Back to AZN

Durvalumab combined with S-1

Phase 2
AstraZeneca PLC (AZN)

Phase 2

Development Phase

1

Upcoming Catalysts

0

Historical Events

0

Regulatory Approvals

Upcoming Catalysts
What are catalysts?
Dec '26
AZNPhase 2

Durvalumab combined with S-1 Phase 2 Est. Readout

Durvalumab combined with S-1
Dec 2026~
CT.gov
00%
Competitive Landscape

1 competitor in Biliary Tract Cancer

View Full Landscape
Drug Information

Target Indication

Biliary Tract Cancer

Clinical Trial

NCT06490107

Last updated: 11/14/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Drug Science
Mechanism of action & safety profile
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts

Weekly digest every Monday. Unsubscribe anytime.